Translational Medicine @ UniSa
Volume 23

Issue 4

Article 5

October 2020

Can we turn off the “Covid-biting-tail” inflammation?
Valentina Giudice
Hematology and Transplant Center, University Hospital “San Giovanni di Dio e Ruggi d’Aragona”, Italy,
vgiudice@unisa.it

Amelia Filippelli
Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Italy,
afilippelli@unisa.it

Carmine Selleri
1Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Italy,
cselleri@unisa.it

Follow this and additional works at: https://tmj.unisa.it/journal
Part of the Chemicals and Drugs Commons

Recommended Citation
Giudice, Valentina; Filippelli, Amelia; and Selleri, Carmine (2020) "Can we turn off the “Covid-biting-tail”
inflammation?," Translational Medicine @ UniSa: Vol. 23 : Iss. 4 , Article 5.
Available at: https://doi.org/10.37825/2239-9747.1006

This Article is brought to you for free and open access by Translational Medicine @ UniSa. It has been accepted for
inclusion in Translational Medicine @ UniSa by an authorized editor of Translational Medicine @ UniSa.

Can we turn off the “Covid-biting-tail” inflammation?
Giudice Valentina1,2,3, Filippelli Amelia1,2, Selleri Carmine1,3
Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, University of Salerno, Italy.
2
Clinical Pharmacology, University Hospital “San Giovanni di Dio e Ruggi d’Aragona”, Italy.
3
Hematology and Transplant Center, University Hospital “San Giovanni di Dio e Ruggi d’Aragona”, Italy.

1

(vgiudice@unisa.it)
Keywords: SARS-CoV-2, Covid-19, inflammation
Dear Editor,
More than 30% of subjects with Covid-19 requires
intensive care unit admission, and in several cases, patients
develop severe respiratory symptoms and an acute
respiratory distress syndrome (ARDS) requiring intensive
care treatment, and precipitating factors are still under
investigation; however, a massive release of proinflammatory cytokines and chemokines from immune
cells is one of the main pathogenetic mechanisms.1 Based
on previous findings in SARS-CoV and Middle East
respiratory syndrome CoV diseases, infected macrophages
can belatedly release high amount of pro-inflammatory
cytokines, especially TNFα and IL-6, and sustain and
enhance inflammatory and immune responses during
SARS-CoV-2
infection
contributing
to
ARDS
development and subsequently to the multiorgan failure
syndrome (MOFS) [1].
The main viral entry mechanism is the binding of
the viral “Spike” protein to the surface AngiotensinConverting Enzyme 2 (ACE-2) receptor on host alveolar
epithelial cells. ACE-2, a zinc containing type I
transmembrane metalloenzyme, regulates blood pressure
through the renin-angiotensin system (RAS), and is highly
expressed on various cell types, such as vascular
endothelial cells and alveolar epithelial cells [2]. Therefore,
SARS-CoV-2 virus infects alveolar cells through ACE-2
receptor binding sequestrating available receptors for RAS
regulation and increasing kinin, complement, and
coagulation cascade activation. The complement system, a
multi-step pathway of the innate immune response, causes
the formation of pores on pathogen membranes inducing
lysis and enhancing phagocytosis by macrophages, and
releases several pro-inflammatory molecules, the
anaphylatoxins, that amplify inflammation and immune
responses [1-2]. Some of those molecules can trigger the
activation of kinin and coagulation cascades which can
sustain vascular permeability and thrombosis also
occurring during ARDS. In addition, vascular permeability
facilitates neutrophil and macrophage recruitment at the
site of viral infection supporting inflammation and tissue
damage. Simultaneously, infected cells trigger adaptive
immune responses, such as Th1 with release of type I
interferons, macrophage recruitment and activation with
release of IL-1 and TNFα. These mechanisms might
increase vascular permeability and neutrophil recruitment

in the site of viral infection with production of large amount
of pro-inflammatory cytokines, especially IL-6, and
anaphylatoxins which sustain inflammation and tissue
damage as in a “dog-biting-tail” system until pulmonary
edema, thrombosis and respiratory distress develop and
progress to ARDS and MOFS (Figure 1).
Currently, there are no specific therapies for
Covid-19; however, a lot of available drugs used in other
diseases, especially autoimmune disorders, are under
investigation for treatment of severe SARS-CoV-2
infection or for prophylaxis [3]. In particular, eculizumab,
an anti-C5a complement factor monoclonal antibody used
for treatment of paroxysmal nocturnal hemoglobinuria, is
currently under investigation in the United States (SOLIDC19 trial NCT04288713) and Italy for treatment of Covid19. Growing evidence of efficacy of eculizumab in SARSCoV-2-related ARDS are accumulating showing a potential
benefit of this drug in reducing platelet consumption and
intravascular coagulation thus preventing thrombosis of
pulmonary capillaries and interstitial pneumonia or
reducing ongoing pulmonary lesions [4]. In addition, Janus
kinase (JAK) inhibitors are under investigation because of
the wide involvement of JAK/STAT pathway in
transducing the signals of several cytokine stimulation,
such as interferons and TNFα [3]. In 2019, the Food and
Drug Administration has approved ruxolitinib, a JAK1/2
inhibitor, for treatment of Graft-versus-Host disease
(GvHD) because ruxolitinib has shown in vitro and in vivo
efficacy in modulating immune responses, especially those
exerted by Natural Killer cells, DCs, Th1 and Th17 cells,
and regulatory T lymphocytes, and in regulating release of
several cytokines including TNFα. Moreover, ruxolitinib
can reduce viral replication, as already described for HIV
in in vitro and mouse models. Preliminary results have
described a fast clinical recovery of Covid-19 patients
treated with ruxolitinib compared to placebo; however,
JAK inhibition might cause severe adverse events,
including cutaneous rash.
Based on the hypothesis that SARS-CoV-2
infection triggers a “dog-biting-tail” inflammatory loop,
the use of a single anti-inflammatory agent might be not
sufficient in severe Covid-19; thus, a combination of drugs

Fig. 1. The “Covid-biting-tail” inflammation.
SARS-CoV-2 infects alveolar cells by binding ACE-2 receptor eliciting a T helper 1 immune response and activation of macrophages with release of
type I interferons (IFNs), interleukin(IL)-1, and tumor necrosis factor alpha (TNFα), contributing to complement cascade activation and tissue damage.
Several products, such as the membrane attack complex (MAC), can enhance the activation of prothrombin to thrombin leading to thrombotic events,
and can sustain tissue damage by facilitating macrophage phagocytosis. These events might trigger (or perpetuate) coagulation cascade which also
sustains complement system activation. C3a and C5a, also known as anaphylatoxins, contribute together with macrophages and Th1 cells to neutrophil
recruitment in the site of viral infection and amplification of inflammatory responses by releasing of several pro-inflammatory mediators. However,
increased vascular permeability is required to facilitate neutrophil recruitment: kinin cascade products play an important role in regulating vascular
permeability, and ACE enzymes can degrade those molecules in non-active peptides. Therefore, viral occupancy of ACE-2 receptors might reduce
regulatory ACE functions, and increase vascular permeability leading to pulmonary edema. Moreover, increased vascular permeability favors
thrombosis and neutrophil recruitment ultimately leading to persistence of inflammation and tissue damage. Ruxolitinib, a JAK1/2 inhibitor, and
eculizumab, an anti-C5a monoclonal antibody, can block this inflammatory circle in multiple steps (some artworks from https://smart.servier.com).

would be advisable in preventing ARDS and
MOFS in intensive care patients. For example, we have
described clinical improvements of six severe Covid-19
cases treated with ruxolitinib 10 mg/twice daily for 14 days
and eculizumab 900 mg IV/weekly for three weeks [5].

Patients treated with the combination showed
significant improvements in respiratory symptoms and
radiographic pulmonary lesions, and decreased levels of
circulating D-dimers while significant increase in platelet
counts. Therefore, eculizumab could reduce complement
and coagulation cascade activation and decrease vascular
permeability and thrombosis on one side; while ruxolitinib
might inhibit Th1 and macrophage activation ultimately
leading to reduced neutrophil recruitment in the site of viral
infection. In conclusion, combined use of antiinflammatory drugs acting on different but connected
pathways during severe Covid-19 might dramatically turn
off inflammation in the lungs thus reducing the risk of
ARDS and MOFS development.
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